An update on telmisartan/hydrochlorothiazide combinations for the management of hypertensive patients with additional cardiovascular risk factors

Sverre Kjeldsen, Giuseppe Mancia, Roland Schmieder, Michaela Mattheus, Thomas Unger

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

International hypertension guidelines endorse the use of combination therapy to achieve blood pressure control in the majority of patients. Angiotensin AT1 receptor blockers, in combination with diuretics, are among the preferred combinations, with telmisartan plus hydrochlorothiazide (HCTZ) being an effective and well-tolerated combination. This article provides an up-to-date review of the existing data on telmisartan/HCTZ combination for the management of hypertension in patients with additional cardiovascular risk factors, including reports emerging from a number of recent clinical trials and secondary analyses of older trials. The accumulated evidence from clinical trials demonstrates that telmisartan/HCTZ combinations are effective and well tolerated in patients with mild-to-severe hypertension, including subgroups of patients with cardiovascular risk factors such as advanced age, obesity, chronic kidney disease, diabetes mellitus and treatment-resistant hypertension.

Original languageEnglish
Pages (from-to)673-682
Number of pages10
JournalExpert Review of Cardiovascular Therapy
Volume11
Issue number6
DOIs
Publication statusPublished - Jun 2013

Fingerprint

Hypertension
Clinical Trials
Angiotensin Type 1 Receptor
Angiotensin Receptor Antagonists
Chronic Renal Insufficiency
Diuretics
Diabetes Mellitus
Obesity
Guidelines
Blood Pressure
hydrochlorothiazide drug combination telmisartan
Therapeutics

Keywords

  • diabetes mellitus
  • high cardiovascular risk
  • hydrochlorothiazide
  • hypertension
  • obesity
  • renal impairment
  • telmisartan

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine

Cite this

An update on telmisartan/hydrochlorothiazide combinations for the management of hypertensive patients with additional cardiovascular risk factors. / Kjeldsen, Sverre; Mancia, Giuseppe; Schmieder, Roland; Mattheus, Michaela; Unger, Thomas.

In: Expert Review of Cardiovascular Therapy, Vol. 11, No. 6, 06.2013, p. 673-682.

Research output: Contribution to journalArticle

Kjeldsen, Sverre ; Mancia, Giuseppe ; Schmieder, Roland ; Mattheus, Michaela ; Unger, Thomas. / An update on telmisartan/hydrochlorothiazide combinations for the management of hypertensive patients with additional cardiovascular risk factors. In: Expert Review of Cardiovascular Therapy. 2013 ; Vol. 11, No. 6. pp. 673-682.
@article{673ab9dac413414b9e02745746c55de0,
title = "An update on telmisartan/hydrochlorothiazide combinations for the management of hypertensive patients with additional cardiovascular risk factors",
abstract = "International hypertension guidelines endorse the use of combination therapy to achieve blood pressure control in the majority of patients. Angiotensin AT1 receptor blockers, in combination with diuretics, are among the preferred combinations, with telmisartan plus hydrochlorothiazide (HCTZ) being an effective and well-tolerated combination. This article provides an up-to-date review of the existing data on telmisartan/HCTZ combination for the management of hypertension in patients with additional cardiovascular risk factors, including reports emerging from a number of recent clinical trials and secondary analyses of older trials. The accumulated evidence from clinical trials demonstrates that telmisartan/HCTZ combinations are effective and well tolerated in patients with mild-to-severe hypertension, including subgroups of patients with cardiovascular risk factors such as advanced age, obesity, chronic kidney disease, diabetes mellitus and treatment-resistant hypertension.",
keywords = "diabetes mellitus, high cardiovascular risk, hydrochlorothiazide, hypertension, obesity, renal impairment, telmisartan",
author = "Sverre Kjeldsen and Giuseppe Mancia and Roland Schmieder and Michaela Mattheus and Thomas Unger",
year = "2013",
month = "6",
doi = "10.1586/erc.13.63",
language = "English",
volume = "11",
pages = "673--682",
journal = "Expert Review of Cardiovascular Therapy",
issn = "1477-9072",
publisher = "Expert Reviews Ltd.",
number = "6",

}

TY - JOUR

T1 - An update on telmisartan/hydrochlorothiazide combinations for the management of hypertensive patients with additional cardiovascular risk factors

AU - Kjeldsen, Sverre

AU - Mancia, Giuseppe

AU - Schmieder, Roland

AU - Mattheus, Michaela

AU - Unger, Thomas

PY - 2013/6

Y1 - 2013/6

N2 - International hypertension guidelines endorse the use of combination therapy to achieve blood pressure control in the majority of patients. Angiotensin AT1 receptor blockers, in combination with diuretics, are among the preferred combinations, with telmisartan plus hydrochlorothiazide (HCTZ) being an effective and well-tolerated combination. This article provides an up-to-date review of the existing data on telmisartan/HCTZ combination for the management of hypertension in patients with additional cardiovascular risk factors, including reports emerging from a number of recent clinical trials and secondary analyses of older trials. The accumulated evidence from clinical trials demonstrates that telmisartan/HCTZ combinations are effective and well tolerated in patients with mild-to-severe hypertension, including subgroups of patients with cardiovascular risk factors such as advanced age, obesity, chronic kidney disease, diabetes mellitus and treatment-resistant hypertension.

AB - International hypertension guidelines endorse the use of combination therapy to achieve blood pressure control in the majority of patients. Angiotensin AT1 receptor blockers, in combination with diuretics, are among the preferred combinations, with telmisartan plus hydrochlorothiazide (HCTZ) being an effective and well-tolerated combination. This article provides an up-to-date review of the existing data on telmisartan/HCTZ combination for the management of hypertension in patients with additional cardiovascular risk factors, including reports emerging from a number of recent clinical trials and secondary analyses of older trials. The accumulated evidence from clinical trials demonstrates that telmisartan/HCTZ combinations are effective and well tolerated in patients with mild-to-severe hypertension, including subgroups of patients with cardiovascular risk factors such as advanced age, obesity, chronic kidney disease, diabetes mellitus and treatment-resistant hypertension.

KW - diabetes mellitus

KW - high cardiovascular risk

KW - hydrochlorothiazide

KW - hypertension

KW - obesity

KW - renal impairment

KW - telmisartan

UR - http://www.scopus.com/inward/record.url?scp=84878832614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878832614&partnerID=8YFLogxK

U2 - 10.1586/erc.13.63

DO - 10.1586/erc.13.63

M3 - Article

VL - 11

SP - 673

EP - 682

JO - Expert Review of Cardiovascular Therapy

JF - Expert Review of Cardiovascular Therapy

SN - 1477-9072

IS - 6

ER -